YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

Not Applicable

Completed

Brief Summary: This study is for men and women have been diagnosed with non-alcoholic fatty liver disease (NAFLD) and will consequently participate in the YMCA's Diabetes Prevention Program.

Detailed Description: This study is for men and women who participate in the YMCA's Diabetes Prevention Program (YMCA's DPP) and have been diagnosed with non-alcoholic fatty liver disease (NAFLD). There will be no administration of study drug. The purpose of this study is to see if participation in the YMCA's DPP will result in weight loss and improvement in the liver in patients with fatty liver disease.

Eligible participants will visit Weill Cornell Medical College's Gastroenterology and Hepatology clinic to review their medical history, physical examination, complete a survey, and conduct imaging tests (FibroScan, ultrasound, DEXA scan) for their baseline visit. Blood will be collected as part of standard practice. An additional blood sample will be collected for storage. Subjects will complete 9 out of 16 weekly sessions. The YMCA's program will be conducted at Weill Cornell Medical College Gastroenterology and Hepatology Division.

Participants will be in the YMCA program for about 1 year and an additional 1 year in the long-term follow-up for data collection.

Participants will be compensated for their time.

Key eligibility criteria:

1. Men and women over 18 years of age.

2. Diagnosed with Non-alcoholic Fatty liver disease.

3. Detailed eligibility reviewed when contacting the study team.

Recruitment & Eligibility

Inclusion Criteria

Age ≥18
Must provide signed written informed consent and agree to comply with the study protocol
BMI >25 kg/m²
Hepatic steatosis by imaging or histology
Baseline Fibroscan CAP score > 238 dB/m
ALT >19IU/mL in females, ALT >30IU/mL in males

Exclusion Criteria

Unclear etiology of liver disease
Competing etiologies for hepatic steatosis
Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:
- Positive hepatitis B surface antigen
- Positive hepatitis C virus RNA
- Suspicion of drug-induced liver disease
- Alcoholic liver disease
- Autoimmune hepatitis
- Wilson's disease
- Hemochromatosis
- Primary biliary cholangitis or primary sclerosing cholangitis
Known or suspected hepatocellular carcinoma
Current or recent history (<5 years) of significant alcohol consumption. For men, significant consumption is defined as >30g of alcohol per day. For women, it is defined as >20g of alcohol per day.
Compensated and decompensated cirrhosis (clinical and/or histologic evidence of cirrhosis). NASH patients with fibrosis stage = 4 according to the NASH CRN fibrosis staging system are excluded.
Pregnant females
Mental instability or incompetence, such that the validity of the informed consent or ability to be compliant with the study is uncertain
Inability to perform Fibroscan and/or invalid study

Arm && Interventions

Group	Intervention	Description
YMCA Class	YMCA class	This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.

Primary Outcome Measures

Name	Time	Method
Effect of the YMCA's Diabetes Prevention Program on NAFLD	104 weeks from the start of the study	Determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program - we'll look at the changes of ALT levels to determine the aforementioned. We will perform these diagnostic tests in order to determine the effectiveness of the 16 weeks of sessions.
Determine if Liver Fat via Fibroscan Controlled Attentuation Pattern score has decreased as a result of YMCA program	104 weeks from the start of the study	Evaluate the amount of liver fat as determined by Fibroscan Controlled Attenuation Pattern (CAP) score in patients with NAFLD pre- and post- participation in the diabetes prevention program with the YMCA. The CAP range should be 100-400, without any sub-scales reported. Lower values in the range represent less 'fat', making it a better score.

Secondary Outcome Measures

Name	Time	Method
Measuring the effectiveness of the YMCA Program, as per SF-36 patient-reported questionnaires	104 weeks from the start of the study	Determine the effect of YMCA's DPP on quality of life in patients with NAFLD as per SF-36 questionnaire.
Measuring the effectiveness of the YMCA Program, as per the DEXA scan	104 weeks from the start of the study	Determine the effect of YMCA's DPP on body composition (aggregated via body fat percentage and lean and fat body mass) using dual-energy X-ray absorptiometry (DEXA).
Measuring the effectiveness of the YMCA Program, as per each patient's BMI	104 weeks from the start of the study	Determine the effect of YMCA's DPP on BMI in patients with NAFLD. We are reporting this as an aggregate of Body Mass Index.
Measuring the effectiveness of the YMCA Program, as per metabolic blood work that's analyzed	104 weeks from the start of the study	Determine the effect of YMCA's DPP on levels of systemic factors linked to the metabolic syndrome. The metabolites that will be studied are all research-related blood work.

Locations (1): Weill Cornell Medical College
🇺🇸
New York, New York, United States